medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (3)

Atopic dermatitis treated with dupilumab in a private dermatological center

Aceves VMA, Ruiz LAB, Crocker SAB, Sánchez DLE, Ramos ÁMP, Santana RNR, Ungson GMG

Language: Spanish
References: 16
Page: 285-292
PDF size: 357.50 Kb.


ABSTRACT

Introduction: atopic dermatitis (AD) is an inflammatory skin disease that negatively impacts the quality of life of affected patients due to the severity of lesions combined with the symptoms of pruritus and xerosis. In patients with moderate to severe disease, symptoms associated with ad cause significant morbidity. In 2017, the Food and Drug Administration (FDA) approved a new biologic (dupilumab) for patients with moderate to severe ad above 18 years old, with inadequate control.
Clinical case: eight clinical cases of patients with severe atopic dermatitis successfully treated with dupilumab are presented, obtaining EASI-90 after 16 weeks of treatment in a private dermatological center in Mexico.
Discussion: dupilumab is an inhibitor of the IL-4 alpha subunit receptor, approved for moderate to severe atopic dermatitis, which has shown excellent results and a good safety profile.
Conclusions: we encourage the knowledge of new treatments to offer the patient better results in their skin diseases.


REFERENCES

  1. Silverberg JI y Hanifin JM, Adult eczema prevalence and associationswith asthma and other health and demographic factors: a USpopulation-based study, Journal of Allergy and Clinical Immunology 2013;132(5):1132-8. Disponible en: https://doi.org/10.1016/j.jaci.2013.08.031.

  2. Bolognia J, Schaffer J y Cerroni L, Dermatology, 2 vols., 4ª ed., Elsevier,2017.

  3. Giavina-Bianchi M, Rizzo LV y Giavina-Bianchi P, Severe atopic dermatitis:dupilumab is not just safer, but more efficient, Allergologiaet Immunopathologia 2020; 48(6):792-7. Disponible en: https://doi.org/10.1016/j.aller.2019.12.005.

  4. Ferreira S y Torres T, Dupilumab para el tratamiento de la dermatitisatópica, Actas Dermo-Sifiliográficas 2018; 109(3): 230-40. Disponible en:https://doi.org/10.1016/j.ad.2017.10.012.

  5. Fenner J y Silverberg NB, Skin diseases associated with atopic dermatitis,Clinics in Dermatology 2018; 36(5): 631-40. Disponible en: https://doi.org/10.1016/j.clindermatol.2018.05.004.

  6. Maloney NJ, Tegtmeyer K, Zhao J y Worswick S, Dupilumab in dermatology:potential for uses beyond atopic dermatitis, Journal of Drugsin Dermatology 2019; 18(10):1053-5.

  7. Was´kiel-Burnat A, Osin´ska M, Salin´ska A, Blicharz L, Goldust M, OlszewskaM y Rudnicka L, The role of serum Th1, Th2, and Th17 cytokinesin patients with alopecia areata: clinical implications, Cells 2021;10(12):3397. Disponible en: https://doi.org/10.3390/cells10123397.

  8. Gooderham MJ, Hong HCH, Eshtiaghi P y Papp KA, Dupilumab: areview of its use in the treatment of atopic dermatitis, Journal of theAmerican Academy of Dermatology 2018; 78(3):S28-S36. Disponible en:https://doi.org/10.1016/j.jaad.2017.12.022.

  9. Rincón-Pérez C, Larenas-Linnemann D, Figueroa-Morales MA, Luna-Pech J, García-Hidalgo L, Macías-Weinmann A, Gómez-Vera J, Barba-Gómez JF, Matta-Campos JJ, Guevara-Sangines E, Jurado-SantacruzF, López Tello-Santillán A, Ortega-Martell JA, Pulido-Díaz N, Serrano-Jaén LG, Toledo-Bahena M, Villanueva-Quintero G y Mayorga-ButrónJL, Consenso mexicano para el diagnóstico y tratamiento de la dermatitisatópica en adolescentes y adultos, Revista Alergia México 2018;65:S8-S88. Disponible en: https://doi.org/10.29262/ram.v65i6.526.

  10. Muzumdar S, Skudalski L, Sharp K y Waldman RA, Dupilumab facialredness/dupilumab facial dermatitis: a guide for clinicians, AmericanJournal of Clinical Dermatology 2021; 23(1):61-7. Disponible en: https://doi.org/10.1007/s40257-021-00646-z.

  11. Kamata M y Tada Y, A literature review of real-world effectivenessand safety of dupilumab for atopic dermatitis, jid Innovations 2021;1(3):100042. Disponible en: https://doi.org/10.1016/j.xjidi.2021.100042.

  12. Aceves Villalvazo MA y Sánchez Dueñas LE, Terapia biológica en dermatología,vol. 1, 1a ed., Editorial Alfil, 2020.

  13. Zubek AE y Vesely MD, Onychodystrophy associated with dupilumabtherapy for atopic dermatitis, jaad Case Reports 2021; 7:20-2.Disponible en: https://doi.org/10.1016/j.jdcr.2020.10.024.

  14. Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M,Martínez-Domenech L y Pérez-Ferriols A, Improvement of alopeciaareata with dupilumab in a patient with severe atopic dermatitis andreview the literature, Australasian Journal of Dermatology 2019; 61(2). Disponibleen: https://doi.org/10.1111/ajd.13208.

  15. Russomanno K y Carver DeKlotz CM, Acceleration of cutaneous tcelllymphoma following dupilumab administration, jaad Case Reports2021; 8:83-5. Disponible en: https://doi.org/10.1016/j.jdcr.2020.12.010.

  16. Barbarin C, Hosteing S, Nosbaum A, Allouchery M y Celerier P, Earlyonset of alopecia areata after dupilumab introduction in a patientwith atopic dermatitis, European Journal of Dermatology 2019; 29(5):542-3.Disponible en: https://doi.org/10.1684/ejd.2019.3626.




2020     |     www.medigraphic.com